Laboratory of Human Carcinogenesis, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):539-544. doi: 10.1158/1055-9965.EPI-19-0792. Epub 2020 Dec 8.
The association of aspirin use with prostate cancer has been investigated, but few studies included African-American men. Here, we analyzed the relationship of aspirin intake with prostate cancer risk and mortality among African-American men in the Southern Community Cohort Study (SCCS).
SCCS recruited 22,426 African-American men between 2002 and 2009. Aspirin use was assessed at enrollment. Our exposures of interest were any aspirin use (regular strength, low-dose or baby aspirin, or half tablets of aspirin) and regular strength aspirin. Each exposure variable was compared with nonusers. Associations between aspirin use and prostate cancer risk and mortality were examined with Cox proportional hazards models.
At enrollment, 5,486 men (25.1%) reported taking any aspirin and 2,634 men (12.1%) reported regular strength aspirin use. During follow-up (median, 13 years), 1,058 men developed prostate cancer, including 103 prostate cancer-specific deaths. Aspirin use was not associated with prostate cancer development [adjusted HR, 1.07; 95% confidence interval (CI), 0.92-1.25 for any aspirin use and HR, 0.97; 95% CI, 0.78-1.19 for regular strength aspirin], but was suggestively associated with reduced prostate cancer mortality (HR, 0.66; 95% CI, 0.39-1.14 for any aspirin use and HR, 0.41; 95% CI, 0.17-1.00 for regular strength aspirin).
Aspirin use at enrollment was tentatively associated with reduced prostate cancer mortality, but not risk, among African-American men in SCCS.
Prospective SCCS data suggest that aspirin use may help prevent lethal prostate cancer among this high-risk group of men.
已对阿司匹林使用与前列腺癌之间的关系进行了研究，但很少有研究纳入非裔美国男性。在此，我们分析了在南方社区队列研究（SCCS）中，阿司匹林摄入与非裔美国男性前列腺癌风险和死亡率之间的关系。
SCCS 在 2002 年至 2009 年间招募了 22426 名非裔美国男性。在入组时评估了阿司匹林的使用情况。我们感兴趣的暴露因素是任何阿司匹林的使用（普通强度、低剂量或小剂量阿司匹林，或阿司匹林半片）和普通强度阿司匹林。将每种暴露变量与未使用者进行比较。使用 Cox 比例风险模型检查阿司匹林使用与前列腺癌风险和死亡率之间的关系。
在入组时，5486 名男性（25.1%）报告服用了任何阿司匹林，2634 名男性（12.1%）报告服用了普通强度阿司匹林。在随访期间（中位数为 13 年），1058 名男性发生了前列腺癌，包括 103 例前列腺癌特异性死亡。阿司匹林的使用与前列腺癌的发生无关[调整后的 HR，1.07；95%置信区间（CI），0.92-1.25，用于任何阿司匹林的使用和 HR，0.97；95%CI，0.78-1.19，用于普通强度阿司匹林]，但与前列腺癌死亡率降低有关（HR，0.66；95%CI，0.39-1.14，用于任何阿司匹林的使用和 HR，0.41；95%CI，0.17-1.00，用于普通强度阿司匹林）。
在 SCCS 中，入组时的阿司匹林使用与非裔美国男性的前列腺癌死亡率降低有关，但与风险无关。
前瞻性 SCCS 数据表明，阿司匹林的使用可能有助于预防这一高危男性群体中的致命性前列腺癌。
